TRVI

Trevi Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website revitherapeutics.com
Employees(FY) 25
ISIN US89532M1018

Performance

+12.5%

+35.0%

+15.71%

+50.56%

+202.24%

YTD

+213.95%

Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio for the treatment of serious cough conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b/3 clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Advanced Technical Analysis

Technical Analysis of TRVI 2024-12-20

The stock exhibits a strong bullish sentiment with a Moving Average Score of 90, indicating robust upward momentum, while the Technical Score of 68 further supports this positive outlook. However, the Oscillators Score of 46 suggests a neutral stance, indicating potential consolidation or a pause in the upward trend, which investors should monit...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of TRVI

Stock Rank

Recent News & Updates

2024-12-15 18:36
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering(Prnewswire)
2024-12-12 18:10
Trevis chronic cough trial in IPF subjects continues without sample size change(Yahoo Finance)
2024-12-11 20:47
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?(Yahoo Finance)
2024-12-11 18:30
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough(Prnewswire)
2024-12-03 03:05
Trevi Therapeutics Announces Positive Topline Results from Human Abuse Potential Study of Oral Nalbuphine(Prnewswire)
2024-11-20 18:30
Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference(Prnewswire)
2024-11-07 00:18
Q3 2024 Trevi Therapeutics Inc Earnings Call(Yahoo Finance)
2024-11-06 13:21
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ...(Yahoo Finance)
2024-11-06 03:05
Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates(Prnewswire)
2024-10-30 04:05
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024(Prnewswire)
2024-10-23 05:02
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc.(Yahoo Finance)
2024-10-20 19:30
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough(Prnewswire)
2024-10-14 19:30
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences(Prnewswire)
2024-10-09 05:58
Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ...(Yahoo Finance)
2024-10-03 04:05
Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program(Prnewswire)
2024-09-30 05:30
Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer(Prnewswire)
2024-09-25 19:30
Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024(Prnewswire)
2024-09-04 04:05
Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024(Prnewswire)
2024-08-29 21:33
Abercrombie upgraded, Dollar General downgraded: Wall Street's top analyst calls(Yahoo Finance)
2024-08-27 19:30
Trevi Therapeutics to Participate in September Investor and Medical Conferences(Prnewswire)
2024-08-08 09:58
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q2 2024(Investorplace)
2024-08-08 04:05
Trevi Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates Reaffirming Clinical Trial Guidance(Prnewswire)
2024-07-31 19:30
Trevi Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Corporate Update on August 8, 2024(Prnewswire)
2024-07-01 19:30
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events(Prnewswire)
2024-05-12 20:57
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-08 19:30
Trevi Therapeutics to Participate in Upcoming Conferences(Prnewswire)
2024-05-07 18:56
Q1 2024 Trevi Therapeutics Inc Earnings Call(Yahoo Finance)
2024-05-07 08:59
TRVI Stock Earnings: Trevi Therapeutics Misses EPS for Q1 2024(Investorplace)
2024-05-07 06:25
Trevi Therapeutics Reports Q1 2024 Financial Results: A Detailed Analysis(Yahoo Finance)
2024-05-07 04:05
Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates(Prnewswire)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.